Transcat buys USD 12.80 million firm while Transcat stock trades at EUR 72.00

Published on 10/20/2026 at 13:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The August 31 acquisition expanded regulated-market reach. Transcat stock costs EUR 72.00 on October 20, 2026 at a USD 755.1 million market value.

Acquisition and earnings calendar

Transcat completed the USD 12.80 million Southeastern Biomedical Associates acquisition on August 31, 2026.
Fiscal first-quarter 2027 revenue reached USD 92.95 million on June 27, 2026.
Transcat stock trades at EUR 72.00 at 1:32 p.m. CEST at Lang & Schwarz on October 20, 2026.
MarketBeat estimates the next results announcement for November 2, 2026.

TRNS, US8935291075, Illustration mit AI erstellt.

Transcat (ISIN US8935291075) was trading at EUR 72.00 at Lang & Schwarz on October 20, 2026, at 1:32 p.m. CEST. On August 31, 2026, the company acquired Southeastern Biomedical Associates for USD 12.80 million, according to Harter Secrest and Emery.

Three dates shaped the story

On June 28, 2026, Wall Street Zen raised Transcat from a sell rating to a hold rating, as reported by MarketBeat. On August 4, 2026, Transcat reported fiscal first-quarter 2027 revenue of USD 92.95 million and adjusted earnings per share of USD 0.51, versus a USD 0.38 consensus estimate, according to MarketBeat. The August 31 acquisition was the latest of the three events and extended the company strategy into regulated biomedical markets.

What does the deal add?

Harter Secrest and Emery said the Southeastern Biomedical Associates transaction advances Transcat's scale in high-cost-of-failure markets, where accredited calibration supports patient safety and regulatory compliance. The operating backdrop was already expanding: StockStory reported that fiscal first-quarter 2027 revenue rose 21.60 percent year over year to USD 92.95 million and exceeded expectations by 7.40 percent.

The margin question is more important than the acquisition headline alone. Transcat operates through calibration and distribution activities, and its most recent quarterly revenue was USD 92.95 million, while MarketBeat reported a 0.99 percent net margin for that quarter. That combination leaves execution and integration as the key measurable issues before the next report.

Next results date and valuation

MarketBeat estimates that Transcat will announce fiscal second-quarter 2027 results on November 2, 2026, after the market closes, with a conference call scheduled for 4:30 p.m. ET. The same page lists consensus expectations of USD 0.4475 earnings per share and USD 92.42 million in revenue, both for fiscal second-quarter 2027.

Stock price and market value

Transcat has a market capitalization of USD 755.1 million as of October 19, 2026. Its 52-week range is USD 50.23 to USD 100.00, putting the current euro quotation below the upper end of that recorded range without combining currencies.

Transcat identifies itself as Nasdaq: TRNS on its investor-relations page, while its business combines calibration services with the distribution of test, measurement, and control instruments. The further course of trading is shown by the continuously updated real-time quote of Transcat stock.